The Deal Register
Database › M&A › ESSA Pharma Inc. Provides Update on its Application to the Supreme…

M&A

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended…

Lane
M&A
Announced
30 Sep 2025
Province
British Columbia
Industry
Healthcare & life sciences
Status
Announced
What the filing says
ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of ESSA (the "Transaction"), ESSA received an amended Interim Order from the Supreme Court of British Columbia (the "Court") on September 25, 2025.
Source

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe